Evidence map›Paper›PMID 31265949›Full record

ArticleMolecular therapy. Nucleic acids2019

Core-Shell Polymer-Based Nanoparticles Deliver miR-155-5p to Endothelial Cells.

Joana C Antunes, Louise Benarroch, Fernanda C Moraes, Maya Juenet, Marie-Sylvie Gross, Mélodie Aubart, Catherine Boileau, Giuseppina Caligiuri, Antonino Nicoletti, Véronique Ollivier and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules.Nanomaterials (Basel, Switzerland) · 2021
    Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Joana C AntunesUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Louise BenarrochUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Fernanda C MoraesUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Maya JuenetUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Marie-Sylvie GrossUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Mélodie AubartUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Catherine BoileauUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Giuseppina CaligiuriUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Antonino NicolettiUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Véronique OllivierUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Frédéric ChaubetUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Didier LetourneurUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France.
Cédric ChauvierreUniversité de Paris, LVTS, INSERM U1148, Université Paris 13, 75018 Paris, France. Electronic address: cedric.chauvierre@inserm.fr.
Université Sorbonne Paris Nord · FRInserm · FRLaboratoire de Recherche Vasculaire Translationnelle · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure occurs in over 30% of the worldwide population and most commonly originates from cardiovascular diseases such as myocardial infarction. microRNAs (miRNAs) target and silence specific mRNAs, thereby regulating gene expression. Because the endogenous miR-155-5p has been ascribed to vasculoprotection, loading it onto positively charged, core-shell poly(isobutylcyanoacrylate) (PIBCA)-polysaccharide nanoparticles (NPs) was attempted. NPs showed a decrease (p < 0.0001) in surface electrical charge (ζ potential), with negligible changes in size or shape when loaded with the anionic miR-155-5p. Presence of miR-155-5p in loaded NPs was further quantified. Cytocompatibility up to 100 μg/mL of NPs for 2 days with human coronary artery endothelial cells (hCAECs) was documented. NPs were able to enter hCAECs and were localized in the endoplasmic reticulum (ER). Expression of miR-155-5p was increased within the cells by 75-fold after 4 hours of incubation (p < 0.05) and was still noticeable at day 2. Differences between loaded NP-cultured cells and free miRNA, at days 1 (p < 0.05) and 2 (p < 0.001) suggest the ability of prolonged load release in physiological conditions. Expression of miR-155-5p downstream target BACH1 was decreased in the cells by 4-fold after 1 day of incubation (p < 0.05). This study is a first proof of concept that miR-155-5p can be loaded onto NPs and remain intact and biologically active in endothelial cells (ECs). These nanosystems could potentially increase an endogenous cytoprotective response and decrease damage within infarcted hearts.

Indexed as

cytoprotectionendothelial cellmicroRNAmyocardial infarctionnanoparticle

Identifiers

PMID31265949
PMCPMC6610682
OpenAlexW2948266412

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.